Regulus Therapeutics Inc. Company Profile
Regulus Therapeutics is a biopharmaceutical company leading the discovery and development of innovative new medicines based on microRNAs. Regulus is targeting microRNAs as a new class of therapeutics by working with a broad network of academic collaborators and leveraging oligonucleotide drug discovery and development expertise from its founding companies Alnylam Pharmaceuticals (Nasdaq:ALNY) and Isis Pharmaceuticals (Nasdaq:ISIS). Regulus is advancing microRNA therapeutics towards the clinic in several areas including hepatitis C infection, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulusâ intellectual property estate contains both the fundamental and core patents in the field and includes over 600 patents and more than 300 pending patent applications pertaining primarily to chemical modifications of oligonucleotides targeting microRNAs for therapeutic applications. In 2008, Regulus entered into a major alliance with GlaxoSmithKline to discover and develop microRNA therapeutics for immuno-inflammatory diseases. In 2010, Regulus entered into a new collaboration with GlaxoSmithKline to develop and commercialize microRNA therapeutics targeting microRNA-122 for the treatment of Hepatitis C Viral infection. For more information, visit http://www.regulusrx.com.
News Articles
Regulus Therapeutics in an IPO for $80.9 million
Regulus Therapeutics summarized its recent financing activity that the company expects will enable Regulus to execute its current strategic objectives for the foreseeable future. In connection with...
Regulus Therapeutics Inc. (NASDAQ:RGLS) raised $45 million through the sale of 11.3 million shares at $4 in an IPO underwritten by Lazard; Cowen; BMO Capital Markets; Needham; and Wedbush. Regulus als...
Regulus Therapeutics Inc. (San Diego, Calif.) and AstraZeneca plc (LSE:AZN; NYSE:AZN) partnered to develop and commercialize preclinical microRNA therapeutics against three targets focused on cardiova...
Regulus adds Biogen to partner roster
Regulus Therapeutics and Biogen Idec have entered into a collaboration to identify microRNAs as biomarkers for multiple sclerosis. Biogen will invest in Regulus and pay the San Diego-based company u...
San Diego’s Regulus Therapeutics Readies for IPO This Week
San Diego’s Regulus Therapeutics is among eight companies on deck at the Nasdaq exchange for IPOs this week, according to a report today from Renaissance Capital, the Connecticut-based institutional...
Regulus Therapeutics announces IPO for $57.5 million
Regulus Therapeutics capped a busy week of deal-making with a proposed initial public offering of $57.5 million, which the biotech would use in part to fund work on its pipeline of microRNA drugs now...
Regulus, Biogen Idec in microRNA deal
Regulus Therapeutics Inc. (La Jolla, Calif.) partnered with Biogen Idec (NASDAQ:BIIB) to identify microRNA biomarkers in blood from multiple sclerosis patients. Regulus said the biomarkers could be us...
San Diego-based Regulus Therapeutics, the developer of microRNA therapies, said today it has formed a research collaboration with UC San Diego. The partners will seek to develop microRNA therapies th...
Drugs and Medications
None
PubMed Articles
We have determined the complete mitochondrial genome (NC_016427) of the Korean red-backed vole, Myodes regulus, which is distributed in South Korea. The total length of the M. regulus mitogenome is 16...
hsa-miR-191 Is a Candidate Oncogene Target for Hepatocellular Carcinoma Therapy.
Hepatocellular carcinoma (HCC) is generally a fatal disease due to a paucity of effective treatment options. The identification of oncogenic microRNAs that exert pleiotropic effects in HCC cells may o...
Clinical Trials
None
Companies
Regulus Therapeutics is a biopharmaceutical company leading the discovery and development of innovative new medicines based on microRNAs. Regulus is targeting microRNAs as a new c...
Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address signi...
More Information about "Regulus Therapeutics Inc." on BioPortfolio
We have published hundreds of Regulus Therapeutics Inc. news stories on BioPortfolio along with dozens of Regulus Therapeutics Inc. Clinical Trials and PubMed Articles about Regulus Therapeutics Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Regulus Therapeutics Inc. Companies in our database. You can also find out about relevant Regulus Therapeutics Inc. Drugs and Medications on this site too.
